Announcement Date: April 9, 2014
Data from: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
http://dx.doi.org/10.5061/dryad.77471
Tamiflu, Relenza, and influenza: what the data do (or don’t) tell us? Dryad Data 2014
Tamiflu, Relenza, and influenza: what the data do (or don’t) tell us
The following is a guest post from Tom Jefferson of The Cochrane Collaboration, Peter Doshi of the University of Maryland and Carl Heneghan from the University of Oxford. We asked them to tell the story behind their recent Cochrane systematic review [1] and dataset in Dryad [2] which holds valuable lessons about the evidence-base on which major public health recommendations are decided. -TJV
In the late 2000s, half the world was busy buying and stockpiling the neuraminidase inhibitors oseltamivir (Tamiflu, Roche) and zanamivir (Relenza, GSK) in fear of an influenza pandemic. (Read More)
Title |
Relenza (Zanamivir) Clinical Study Reports |
Downloaded |
|
Description |
Full set of clinical study reports for the neuraminidase inhibitor Relenza (Zanamivir) produced by GlaxoSmithKline and made available to the Cochrane collaboration for the production of their meta-analysis of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children |
Download |
Relenza.zip (532.2 Mb) |
Download |
README.txt (8.83 Kb) |
Details |
View File Details |
Title |
Tamiflu (oseltamivir) clinical study reports |
Downloaded |
|
Description |
Full set of clinical study reports for the neuraminidase inhibitor Tamiflu (Oseltamivir) produced by Roche and made available to the Cochrane collaboration for the production of their meta-analysis of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children |
Download |
README.txt (2.84 Kb) |
Download |
Tamiflu.zip (741.8 Mb) |
Details |
View File Details |